Leaders in Pharmaceutical Business Intelligence (LPBI) Group

AVIVA LEV-ARI, PhD, RN

avivalev-ari@alum.berkeley.edu

83 Mandalay Road, Newton, Massachusetts  02459 Phone 617-244-4024

http://www.linkedin.com/in/avivalevari

 

Highlights

Performing the role of Senior Manager Scientific & Medical Affairs. Strong expertise in the Cardiovascular Therapeutic Area. Advanced pharmaceutical competitive intelligence skills and interests in drug discovery, medical information, Pharmaceutical R&D, innovations brought to market. Experienced healthcare services delivery provider. Business development & strategy creator for cardiac & vascular medical devices.

Cardiovascular Therapeutic Area / Clinical Experience

• R&D Management Experience 1985-2004
• Cardiovascular Pharmacological Therapy Research 2006 – Present
• Pharmaceutical Business Intelligence 2007- Present
• Clinical Cardiovascular Observational Experience 2005 – 2006

Brigham and Women’s Hospital, Boston. MA                                              June 2006-November 2006

Cardiac ICU, Coronary Care Unit, Medical Rounds [100 hours]

Brigham and Women’s Hospital, Boston. MA                                              March 2006-August 2006

CDIC – Cardiovascular Diagnostic and Interventional Center

Angiography & Interventional Radiology [100 hours]

Mass General Hospital, Boston 1/2005

Cardiac Catheterization Lab

Mass General Hospital, Boston 1/2005

Cardiac Surgery – Operating Room

Texas Heart Institute, Houston, TX 2/2005

Cardiac Surgery – Operating Room at THI

Clinical Nursing Management Experience in Cardiac & Post Acute – Healthcare services delivery to

      Cardiac patients 2008-2012

• Clinical Training Experience: as Staff Development Coordinator, as Nursing Supervisor and as Clinical Nurse Manager

      Nurse Manager 2008-2012

• Experienced in Online Clinical Instructions Systems, 2008 – 2012
• Medical Services Delivery Electronic Platforms: PCC, ECS, 2008 – 2012

Key Achievements, 2012 – Present

• Editor-in-Chief, BioMedicine Electronic Book Series –Thirteen Titles, Amazon-KINDLE, 2013
• BioMed e-Series of e-Books
  https://pharmaceuticalintelligence.com/biomed-e-books/
  
  Perspectives on Nitric Oxide in Disease Mechanisms
  Cardiovascular Diseases: Causes, Risks and Management
  Human Immune System in Health and in Disease
  Metabolic Genomics & Pharmaceutics
  Infectious Disease & New Antibiotic Targets
  Cancer Biology and Genomics for Disease Diagnosis
  Nanotechnology in Drug Discovery and Drug Delivery
  Genomics Orientations for Personalized Medicine
• Thirteen E-Books in BioMed e-Series, on Cardiovascular Diseases, four volumes, in BioMed e-Books Series, Amazon-KINDLE, 2013 – Present

Comprehensive reviews of Innovations in Cardiovascular Medicine, latest discoveries in Cardiac Medical Imaging, Regenerative Medicine, Pharmacotherapy, Medical Devices for Cardiac Repair, Genomics, and related opportunities for Targeted Therapy written by Experts, Authors, Writers.

• Founding Director of Leadership in Pharmaceutical Business Intelligence

Launched in 2/2012 an Open Access Scientific Journal in medicine, technology and business. Multi-expert authoring environment for information syndication in several domains of Life Sciences, Medicine, Pharmaceutical and Healthcare Industries, BioMedicine, Medical Technologies & Devices. Scientific critical interpretations and original articles are written by PhDs, MDs, MD/PhDs, PharmDs, Technical MBAs as Experts, Authors, Writers (EAWs) on an Equity Sharing basis.

http://www.pharmaceuticalIntelligence.com

 

CARDIOVASCULAR PHARMACOLOGICAL THERAPY RESEARCH COMPETENCIES

• Macrovascular Disease – Therapeutic Potential of cEPCs – Reduction methods for CV risk
• Therapeutic Strategy for cEPCs Endogenous Augmentation: A Concept-based Treatment Protocol for a Combined Three Drug Regimen
• Drug therapyfor Hypertension
• Biomarker for Therapeutic Targets of Cardiovascular Risk Reduction by cEPCs Endogenous Augmentation

Management and Executive Functions

PUBLIC SPEAKER AND CONFERENCE PRESENTER

An excellent communicator and a winner of three achievement awards by Dale Carnegie Executive Leadership Program. Able Toast Master.

• Engaging presenter with excellent oral communicator. Delivery of over 200 Technical Presentations (Invited Lectured), 1984-2004.
• Presenter to the CEO of SRI, International, the CEO of Amdahl Corporation and Ross Perot at PSC.

Presented to executives of the leading INDUSTRY ANALYSTS and KOL companies:
–  CEO of Forrester,
–  CEO of the Yankee Group,
–  CEO of the Meta Group,
–  Patricia Sybold and
–  CEO of the Gartner Group.

MANAGEMENT OF TECHNICAL CENTERS AND PRACTICES or DEPARTMENTS

Exercised Operational Management methods and demonstrated Team Leadership and People Leadership while heading a group of 120 professionals at MITRE and over 50 professionals at McGraw-Hill. Professionally trained Planner, strong expertise in Planning and Tracking. Delivered new technology solutions in startup and Fortune 100.

More than 20 years of work related experience in high-tech product management, product marketing, sales and engineering with an emphasis on field disciplines, +20 years of Corporate experience in strategic management consulting and operations management including financial applications, Management of Technical Centers, Management of Research Department,1985-2004. Proven history of success in DIRECTOR level positions

• Seasoned technology executive with proven expertise running collaborative teams in R&D and Operations in the areas of Pharmaceutical, Life Sciences and Healthcare.
• Launched Leaders in Pharmaceutical Business Intelligence Group on LinkedIn
• Strong team builder, leader, and sound communicator who holds outstanding analytical skills, extensive problem solving experience, and a persistent motivation to exceed objectives and drive complex projects to completion and profitability.  Strategic thinker and skilled presenter who has proven effective interaction at all levels of an organization and across organizations.
• Worked with Start-ups and Fortune 100 companies making presentations at the CEO Board Room level. Start ups: TimeØ Group, Concept Five Technologies, Inc., MDSS, Inc.; Top Tier Management Consulting: SRI International, Monitor Group; OEM: Amdahl Corporation; Top 6th System Integrator: Perot System Corporation; FFRDC: MITRE Corporation. In the Publishing industry: McGraw-Hill/CTB. Hospitals and Healthcare delivery Facilities and Pharmaceutical Information Exchange.

MARKETING SKILLS AND INDUSTRY MARKETS DOMAIN KNOWLEDGE

• Technical Competency comprises of in-depth knowledge of software and solutions development processes.
• Marketing Competency comprises of demonstrated experience in market strategy and market research.
• Sales Competency comprises demonstrated experience in conceptual selling, technical selling and sales support (Amdahl Corporation and Perot Systems Corporation).
• Pharmaceutical Industry: Cardiovascular Drugs 

 

Education 

• PhD, 1983

College of Letters & Science

UNIVERSITY OF CALIFORNIA, BERKELEY, Berkeley, California

• Exchange Program, 1980-1981

STANFORD UNIVERSITY, GRADUATE SCHOOL OF BUSINESS & UNIVERSITY OF CALIFORNIA, BERKELEY

• Biological Sciences, 2005

School of Professional and Continuing Studies

NORTHEASTERN UNIVERSITY, Boston, MA

• Direct Entry Graduate Nursing Program, 2007 – MA Registered Nurse Lic #280191

Bouve College of Health Sciences, School of Nursing

NORTHEASTERN UNIVERSITY, Boston, MA

Professional Experience

Founder & Director of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, 2/2012 – Present

LPBI Group, Newton, MA

Manager of an Online Information Exchange on Pharmaceutical, Life Sciences and HealthCare

http://pharmaceuticalintelligence.com

• Recruit Scientists as Expert Author Writers on 25 Categories of research in Pharmaceutical
• Generate Content on Cardiovascular Disease
• Site Statistics: ~1.4 Million e-Readers on 3/6/2018
• Perform Business Development to position the venture for M&A with a Pharma or a Scientific Publisher
• Group Manager on LinkedIn Leaders in Pharmaceutical Business Intelligence Group
• Marketing the Pharmaceutical Intelligence Exchange on the Internet

Manager of a BioMedicine e-Book Series as Editor-in-Chief

Organizer of Scientific Delegations for Patent holders in Pharmaceuticals and Medical Devices

Manager of a Joint venture with an Oncology Database company based in Los Angeles

 

Nurse Management Positions in Acute and Post Acute HealthCare facilities, 8/2008 – 2/2012

Long Term Sub-acute & Rehab RN – Nurse Manager work Experience

• Nurse ManagerLong Term Care Station 3 & 4 – Seventy patients at Belmont Manor,

Belmont, MA, 3/2011- 10/2011

• Unit Manager–Unit LTC at SunBridge HealthCare, Saugus, MA, 2/2010 – 7/2010

Unit Manager –Unit LTC at Kindred HealthCare, Tower Hill, Canton, MA, 9/2010 – 12/2010

• House Nursing Supervisorat Kindred Laurel Ridge, Jamaica Plain, MA, 4/2009  6/2009
• Charge Nurse, Maristhill Nursing and Rehabilitation Center, Waltham, MA, 11/2011 – 2/2012
• Charge Nurse, Interim SDC and Infection Control Coordinator at Armenian Nursing & Rehab Center, 7/2008-12/2008, 9/2009-11/2009

Long Term Acute Hospital (LTACH) work experience

• Nursing Supervisor, Kindred Waltham Hospital, Waltham, MA, 11/2008 – 3/2009 

ACUTE SURGERY Staff Nurse work experience 5/2008 – 7/2008

• Beth Israel Medical Center

ICU, Critical Care and Cardiac training and work experience

• MGH –Cardiac – Step Down Floor, 5/2007 – 9/2007
• Faulkner Hospitals – ICU, 9/2007 – 12/2007

HealthCare Consultant & Academic Cardiovascular Researcher, 9/2006 – 12/2007

• MDSS, Boston, MA and
• Northeastern University, Boston, MA

 

Corporate Work Experience 1985 – 2005

Consultant to the CEO on Advanced Technologies

2/2004 – 10/2004

SGI, INC., NEW YORK, NY

 

Director of Research Methods and Applications

5/2002 – 6/2003

McGRAW-HILL/CTB, Research Department, Monterey, CA

Provided leadership and direction to the development and maintenance of Research technologies, in three areas: Scientific Software, Scientific Methods. Enterprise Technology Renewal initiative.

 

Director, Information Analytics Practice, Electronic Commerce Analytics

3/1997 – 1/2001

PEROT SYSTEMS CORPORATION, Time0 Group, Cambridge, MA,

Designed a state-of-the-art platform for data mining, the platform included churn management, yield analysis, the measurement of connection density, and network topology analysis, utilizing neural networks and genetics algorithms.

• Big Data Analytics Expert Predictive Analytics Predictive Modeling
• Strategic Marketing of Value-Added Internet Analytics Services
• Creation of Auction Analytics, analytics for exchanges
• Dynamic Product Portfolio Management:  Formed supply and demand chain

 

Director, Advanced Information Systems Development

3/1996 – 11/1996

CONCEPT FIVE TECHNOLOGIES, INC., Burlington, Massachusetts

A system engineering commercial start-up and a spin-off from the MITRE Corporation in Bedford, Massachusetts.

Developed the first General Transaction Architecture for trade in intangible goods like eServices, in particular, Analytical eServices.

• Formation of a Detailed Plan for an Electronic MALL for Analytics This platform has potential for content hosting of numerical analysis in several domains, such as financial analytics and computational biology.
• Business Case Generation:  Created the business case for the general transaction architecture and the system

 

Principal Scientist, Head of Research

6/1995 – 3/1996

MITRE CORPORATION, Bedford, Massachusetts

The Economic and Decision Analysis Center (EDAC) – a Technical Center of 120-MTS

• Managed the R&D plan, designed a new organizational structure and planned the center’s resource allocation.  Concluded a strategy and structure redesign for MITRE’s EDAC which positioned the research function as a stand-alone practice with applications in six domains.
• Chartered the Research Future direction on new advances in methodology and their applications to the company’s economic and decision analysis center work program. Methodologies targeted for implementation in new application developments included genetic algorithms, simulated annealing, neural networks, and fuzzy sets.

 

VP R&D

7/1991 – 12/1994

MULTIDIMENSIONAL STRATEGIC SYSTEMS, INC., Newton, MA

Decision Support System Design Competencies

• R&D practice development for Analytical Services
• Designer of intelligent Algorithm-based decision support systems, Internet information       analytics, supply chain management (SCM), CRM, eCRM, data mining modeling

 

Senior Management Consultant

11/1990 – 6/1991

MONITOR COMPANY, Cambridge, Massachusetts

Planning Methodologies, Product Development and Integration,

 

Project Leader

9/1988 – 11/1990

AMDAHL CORPORATION, Sunnyvale, California

Processor Products: Corporate Marketing Demand Forecasting Project

 

Program Director, Business and Economic Statistics

6/1985 – 9/1988

SRI INTERNATIONAL (STANFORD RESEARCH INSTITUTE), Menlo Park, California

Business and Economics Statistics Program

• Created and then managed the Business and Economic Statistics Program adding new capabilities in quantitative oriented business planning
• Worked over a decade with the new paradigm in statistics called Multidimensional Scaling in conjunction with Knowledge Engineering and Expert Opinion Databases

 

Professional Affiliations / Associations

• Medical Science Liaison Society 2012-Present
• American Nursing Association, 2008- Present
• MARN – 2008 – Present

 

Publications 

e-Books in Medicine

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

 

Amazon’s Aviva Lev-Ari Page

 

Collection of Links to electronic Table of Contents (eTOCs) for 16 Volumes:

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

 

 Article Publications and Invited Lectures

• Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence
• List of Invited Lectures, 1983 -2004
• List of Publications, 1983 – 2004
• List of Publications, 2006 – Present
• Cardiovascular Diseases and Pharmacological Therapy: Curations
• MedTech & Medical Devices for Cardiovascular Repair – Curations
• Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
• Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
• Cancer Research: Curations and Reporting

 

AWARDS ON MULTI SECTOR RECORD OF INNOVATIONS AND THOUGHT LEADERSHIP 

• Individual contributor work is mentioned in TWO Corporate Annual Reports:
  – SRI International, 1987;
  – Perot Systems Corporation, 1999
• Individual contribution for SRI Client, GM, was selected as a subject for a professionally made Movie, SRI, 1987 (VCR Cassette available), presented at SRI International Board of Directors Annual Meeting, April 1987
• Excellence Performance Award – Amdahl Corporation, May 1989

Selective Publication Samples

CARDIOVASCULAR DISEASE – DRUG THERAPY OPTIONS

Lev-Ari, A. 5/7/2013 On Devices and On Algorithms: Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset

http://pharmaceuticalintelligence.com/2013/05/07/on-devices-and-on-algorithms-arrhythmia-after-cardiac-surgery-prediction-and-ecg-prediction-of-paroxysmal-atrial-fibrillation-onset/

Lev-Ari, A. 5/4/2013 Cardiovascular Diseases: Decision Support Systems for Disease Management Decision Making

http://pharmaceuticalintelligence.com/2013/05/04/cardiovascular-diseases-decision-support-systems-for-disease-management-decision-making/

Lev-Ari, A. 5/3/2013 Gene, Meis1, Regulates the Heart’s Ability to Regenerate after Injuries.

http://pharmaceuticalintelligence.com/2013/05/03/gene-meis1-regulates-the-hearts-ability-to-regenerate-after-injuries/

Lev-Ari, A. 4/30/2013 Prostacyclin and Nitric Oxide: Adventures in Vascular Biology – A Tale of Two Mediators

http://pharmaceuticalintelligence.com/2013/04/30/prostacyclin-and-nitric-oxide-adventures-in-vascular-biology-a-tale-of-two-mediators/

Lev-Ari, A. 4/28/2013 Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

http://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/

Lev-Ari, A. 4/25/2013 Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association

http://pharmaceuticalintelligence.com/2013/04/25/economic-toll-of-heart-failure-in-the-us-forecasting-the-impact-of-heart-failure-in-the-united-states-a-policy-statement-from-the-american-heart-association/

Lev-Ari, A. 4/24/2013 Harnessing New Players in Atherosclerosis to Treat Heart Disease

http://pharmaceuticalintelligence.com/2013/04/25/harnessing-new-players-in-atherosclerosis-to-treat-heart-disease/

Lev-Ari, A. 4/25/2013 Revascularization: PCI, Prior History of PCI vs CABG

http://pharmaceuticalintelligence.com/2013/04/25/revascularization-pci-prior-history-of-pci-vs-cabg/

Lev-Ari, A. 4/7/2013 Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD

http://pharmaceuticalintelligence.com/2013/04/07/cholesteryl-ester-transfer-protein-cetp-inhibitor-potential-of-anacetrapib-to-treat-atherosclerosis-and-cad/

Lev-Ari, A. 4/4/2013 Hypertriglyceridemia concurrent Hyperlipidemia: Vertical Density Gradient Ultracentrifugation a Better Test to Prevent Undertreatment of High-Risk Cardiac Patients

http://pharmaceuticalintelligence.com/2013/04/04/hypertriglyceridemia-concurrent-hyperlipidemia-vertical-density-gradient-ultracentrifugation-a-better-test-to-prevent-undertreatment-of-high-risk-cardiac-patients/

Lev-Ari, A. 4/3/2013 Fight against Atherosclerotic Cardiovascular Disease: A Biologics not a Small Molecule – Recombinant Human lecithin-cholesterol acyltransferase (rhLCAT) attracted AstraZeneca to acquire AlphaCore

http://pharmaceuticalintelligence.com/2013/04/03/fight-against-atherosclerotic-cardiovascular-disease-a-biologics-not-a-small-molecule-recombinant-human-lecithin-cholesterol-acyltransferase-rhlcat-attracted-astrazeneca-to-acquire-alphacore/

Lev-Ari, A. 3/31/2013 High-Density Lipoprotein (HDL): An Independent Predictor of Endothelial Function & Atherosclerosis, A Modulator, An Agonist, A Biomarker for Cardiovascular Risk

http://pharmaceuticalintelligence.com/2013/03/31/high-density-lipoprotein-hdl-an-independent-predictor-of-endothelial-function-artherosclerosis-a-modulator-an-agonist-a-biomarker-for-cardiovascular-risk/

Lev-Ari, A. 3/10/2013 Acute Chest Pain/ER Admission: Three Emerging Alternatives to Angiography and PCI

http://pharmaceuticalintelligence.com/2013/03/10/acute-chest-painer-admission-three-emerging-alternatives-to-angiography-and-pci/

Lev-Ari, A. and L H Bernstein 3/7/2013 Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/

Lev-Ari, A. 2/28/2013 The Heart: Vasculature Protection – A Concept-based Pharmacological Therapy including THYMOSIN

http://pharmaceuticalintelligence.com/2013/02/28/the-heart-vasculature-protection-a-concept-based-pharmacological-therapy-including-thymosin/

Lev-Ari, A. 2/27/2013 Arteriogenesis and Cardiac Repair: Two Biomaterials – Injectable Thymosin beta4 and Myocardial Matrix Hydrogel

http://pharmaceuticalintelligence.com/2013/02/27/arteriogenesis-and-cardiac-repair-two-biomaterials-injectable-thymosin-beta4-and-myocardial-matrix-hydrogel/

Lev-Ari, A. (2012ab). Coronary artery disease in symptomatic patients referred for coronary angiography: Predicted by Serum Protein Profiles

http://pharmaceuticalintelligence.com/2012/12/29/coronary-artery-disease-in-symptomatic-patients-referred-for-coronary-angiography-predicted-by-serum-protein-profiles/

Bernstein, HL and Lev-Ari, A.  (2012z). Special Considerations in Blood Lipoproteins, Viscosity, Assessment and Treatment

http://pharmaceuticalintelligence.com/2012/11/28/special-considerations-in-blood-lipoproteins-viscosity-assessment-and-treatment/

 Lev-Ari, A. (2012Y) Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes

http://pharmaceuticalintelligence.com/2012/11/13/peroxisome-proliferator-activated-receptor-ppar-gamma-receptors-activation-pparγ-transrepression-for-angiogenesis-in-cardiovascular-disease-and-pparγ-transactivation-for-treatment-of-dia/

Lev-Ari, A. (2012X). Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?

http://pharmaceuticalintelligence.com/2012/10/19/clinical-trials-results-for-endothelin-system-pathophysiological-role-in-chronic-heart-failure-acute-coronary-syndromes-and-mi-marker-of-disease-severity-or-genetic-determination/ 

Lev-Ari, A. (2012W). Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation

http://pharmaceuticalintelligence.com/2012/10/04/endothelin-receptors-in-cardiovascular-diseases-the-role-of-enos-stimulation/

 Lev-Ari, A. (2012V). Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography

http://pharmaceuticalintelligence.com/2012/10/04/inhibition-of-et-1-eta-and-eta-etb-induction-of-no-production-and-stimulation-of-enos-and-treatment-regime-with-ppar-gamma-agonists-tzd-cepcs-endogenous-augmentation-for-cardiovascular-risk-reduc/

Lev-Ari, A. (2012U). Cardiovascular Outcomes: Function of circulating Endothelial Progenitor Cells (cEPCs): Exploring Pharmaco-therapy targeted at Endogenous Augmentation of cEPCs

http://pharmaceuticalintelligence.com/2012/08/28/cardiovascular-outcomes-function-of-circulating-endothelial-progenitor-cells-cepcs-exploring-pharmaco-therapy-targeted-at-endogenous-augmentation-of-cepcs/

Lev-Ari, A. (2012T). Endothelial Dysfunction, Diminished Availability of cEPCs, Increasing CVD Risk for Macrovascular Disease – Therapeutic Potential of cEPCs

http://pharmaceuticalintelligence.com/2012/08/27/endothelial-dysfunction-diminished-availability-of-cepcs-increasing-cvd-risk-for-macrovascular-disease-therapeutic-potential-of-cepcs/

Lev-Ari, A. (2012S). Vascular Medicine and Biology: CLASSIFICATION OF FAST ACTING THERAPY FOR PATIENTS AT HIGH RISK FOR MACROVASCULAR EVENTS Macrovascular Disease – Therapeutic Potential of cEPCs

http://pharmaceuticalintelligence.com/2012/08/24/vascular-medicine-and-biology-classification-of-fast-acting-therapy-for-patients-at-high-risk-for-macrovascular-events-macrovascular-disease-therapeutic-potential-of-cepcs/

Lev-Ari, A. (2012O). Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers

http://pharmaceuticalintelligence.com/2012/07/30/biosimilars-intellectual-property-creation-and-protection-by-pioneer-and-by-biosimilar-manufacturers/

Lev-Ari, A. (2012P). Biosimilars: Financials 2012 vs. 2008

http://pharmaceuticalintelligence.com/2012/07/30/biosimilars-financials-2012-vs-2008/

Lev-Ari, A. (2012Q). Biosimilars: CMC Issues and Regulatory Requirements

http://pharmaceuticalintelligence.com/2012/07/29/biosimilars-cmc-issues-and-regulatory-requirements/

Lev-Ari, A. (2012L). Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production

http://pharmaceuticalintelligence.com/2012/07/19/cardiovascular-disease-cvd-and-the-role-of-agent-alternatives-in-endothelial-nitric-oxide-synthase-enos-activation-and-nitric-oxide-production/

Lev-Ari, A. (2012a). Resident-cell-based Therapy in Human Ischaemic Heart Disease: Evolution in the PROMISE of Thymosin beta4 for Cardiac Repair

http://pharmaceuticalintelligence.com/2012/04/30/93/

Lev-Ari, A. (2012b). Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes

http://pharmaceuticalintelligence.com/2012/05/29/445/

Lev-Ari, A. (2012h). Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk

http://pharmaceuticalintelligence.com/2012/07/02/macrovascular-disease-therapeutic-potential-of-cepcs-reduction-methods-for-cv-risk/

Lev-Ari, A. (2012j) Mitochondria Dysfunction and Cardiovascular Disease – Mitochondria: More than just the “powerhouse of the cell”

http://pharmaceuticalintelligence.com/2012/07/09/mitochondria-more-than-just-the-powerhouse-of-the-cell/

Lev-Ari, A. (2012i). Bystolic’s generic Nebivolol – positive effect on circulating Endothelial Proginetor Cells endogenous augmentation

http://pharmaceuticalintelligence.com/2012/07/16/bystolics-generic-nebivolol-positive-effect-on-circulating-endothilial-progrnetor-cells-endogenous-augmentation/

Lev-Ari, A. & Abourjaily, P. (2006a) “An Investigation of the Potential of circulating Endothelial Progenitor Cells (cEPC) as a Therapeutic Target for Pharmacologic Therapy Design for Cardiovascular Risk Reduction.”Part I: Macrovascular Disease – Therapeutic Potential of cEPCs – Reduction methods for CV risk. Part II: (2006b) Therapeutic Strategy for cEPCs Endogenous Augmentation: A Concept-based Treatment Protocol for a Combined Three Drug Regimen. Part III: (2006c) Biomarker for Therapeutic Targets of Cardiovascular Risk Reduction by cEPCs Endogenous Augmentation using New Combination Drug Therapy of Three Drug Classes and Several Drug Indications. Northeastern University, Boston, MA 02115

Heart Vasculature (2007) Regeneration and Protection of Coronary Artery Endothelium and Smooth Muscle: A Concept-based Pharmacological Therapy of a Combined Three Drug Regimen. Bouve College of Health Sciences, Northeastern University, Boston, MA 02115

 

CARDIOVASCULAR MEDICAL DEVICES

Lev-Ari, A. 5/7/2013 On Devices and On Algorithms: Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset

http://pharmaceuticalintelligence.com/2013/05/07/on-devices-and-on-algorithms-arrhythmia-after-cardiac-surgery-prediction-and-ecg-prediction-of-paroxysmal-atrial-fibrillation-onset/

 

Lev-Ari, A. 5/4/2013 Cardiovascular Diseases: Decision Support Systems for Disease Management Decision Making

http://pharmaceuticalintelligence.com/2013/05/04/cardiovascular-diseases-decision-support-systems-for-disease-management-decision-making/

 

Lev-Ari, A. 5/3/2013 Gene, Meis1, Regulates the Heart’s Ability to Regenerate after Injuries.

http://pharmaceuticalintelligence.com/2013/05/03/gene-meis1-regulates-the-hearts-ability-to-regenerate-after-injuries/

 

Lev-Ari, A. 4/30/2013 Prostacyclin and Nitric Oxide: Adventures in Vascular Biology – A Tale of Two Mediators

http://pharmaceuticalintelligence.com/2013/04/30/prostacyclin-and-nitric-oxide-adventures-in-vascular-biology-a-tale-of-two-mediators/

Lev-Ari, A. 4/28/2013 Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

http://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/

Lev-Ari, A. 4/25/2013 Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association

http://pharmaceuticalintelligence.com/2013/04/25/economic-toll-of-heart-failure-in-the-us-forecasting-the-impact-of-heart-failure-in-the-united-states-a-policy-statement-from-the-american-heart-association/

Lev-Ari, A. 4/24/2013 Harnessing New Players in Atherosclerosis to Treat Heart Disease

http://pharmaceuticalintelligence.com/2013/04/25/harnessing-new-players-in-atherosclerosis-to-treat-heart-disease/

Lev-Ari, A. (2012aa). Renal Sympathetic Denervation: Updates on the State of Medicine

http://pharmaceuticalintelligence.com/2012/12/31/renal-sympathetic-denervation-updates-on-the-state-of-medicine/

Lev-Ari, A. (2012U). Imbalance of Autonomic Tone: The Promise of Intravascular Stimulation of Autonomics

http://pharmaceuticalintelligence.com/2012/09/02/imbalance-of-autonomic-tone-the-promise-of-intravascular-stimulation-of-autonomics/

Lev-Ari, A. (2012R). Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents http://pharmaceuticalintelligence.com/2012/08/13/coronary-artery-disease-medical-devices-solutions-from-first-in-man-stent-implantation-via-medical-ethical-dilemmas-to-drug-eluting-stents/

Lev-Ari, A. (2012K). Percutaneous Endocardial Ablation of Scar-Related Ventricular Tachycardia

http://pharmaceuticalintelligence.com/2012/07/18/percutaneous-endocardial-ablation-of-scar-related-ventricular-tachycardia/

Lev-Ari, A. (2012C). Treatment of Refractory Hypertension via Percutaneous Renal Denervation

http://pharmaceuticalintelligence.com/2012/06/13/treatment-of-refractory-hypertension-via-percutaneous-renal-denervation/

Lev-Ari, A. (2012D). Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS)

http://pharmaceuticalintelligence.com/2012/06/22/competition-in-the-ecosystem-of-medical-devices-in-cardiac-and-vascular-repair-heart-valves-stents-catheterization-tools-and-kits-for-open-heart-and-minimally-invasive-surgery-mis/

Lev-Ari, A. (2012E). Executive Compensation and Comparator Group Definition in the Cardiac and Vascular Medical Devices Sector: A Bright Future for Edwards Lifesciences Corporation in the Transcatheter Heart Valve Replacement Market

http://pharmaceuticalintelligence.com/2012/06/19/executive-compensation-and-comparator-group-definition-in-the-cardiac-and-vascular-medical-devices-sector-a-bright-future-for-edwards-lifesciences-corporation-in-the-transcatheter-heart-valve-replace/

Lev-Ari, A. (2012F). Global Supplier Strategy for Market Penetration & Partnership Options (Niche Suppliers vs. National Leaders) in the Massachusetts Cardiology & Vascular Surgery Tools and Devices Market for Cardiac Operating Rooms and Angioplasty Suites

http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-partnership-options-niche-suppliers-vs-national-leaders-in-the-massachusetts-cardiology-vascular-surgery-tools-and-devices-market-for-car/

Lev-Ari, A. (2012G).  Heart Remodeling by Design: Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony

http://pharmaceuticalintelligence.com/2012/07/23/heart-remodeling-by-design-implantable-synchronized-cardiac-assist-device-abiomeds-symphony/

Lev-Ari, A. (2006S). First-In-Man Stent Implantation Clinical Trials & Medical Ethical Dilemmas. Bouve College of Health Sciences, Northeastern University, Boston, MA 02115